Randomized phase II trial of TS-1 monotherapy versus TS-1 plus gemcitabine therapy in patients with gemcitabine-resistant advanced pancreatic cancer - KCGCOR-1

Keio University School of Medicine, Department of Medicine, Division of Gastroenterology0 个研究点目标入组 80 人开始时间: 2008年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Exclusion criteria are as follows: 1) Prior history of radiation therapy to pancreatic cancer 2) Presence of other active malignancy 3) Presence of severe complications such as plumonary fibrosis, interstitial pneumonia, intestinal paralysis, uncontrolled diabetes, uncontrolled hypertension, myocardial infarction within six months, unstable angina, severe infection, renal failure, liver failure, , etc 4) Past history of allergic reaction to gemcitabine 5) Regular use of frucitocin, fenitoin or warfarin 6) Past history of radiation therapy to the lung(s). 7) Massive ascites or pleural effusion 8) Severe diarrhea 9) active intestinal bleeding 10) Pregnancy, breast feeding, or women who desire to preserve fecundity or men who desire to have children 11) Severe mental disorder 12) regular use of steroids 13) Inadequate physical condition, as diagnosed by primary physician

发起方

Keio University School of Medicine, Department of Medicine, Division of Gastroenterology